PNPLA3 – Medxy AI

Cryptogenic Steatotic Liver Disease: Characterizing a Lean Phenotype Linked to Increased Liver-Related Mortality

By MedXY 08/16/2026

Cryptogenic steatotic liver disease (SLD), representing a lean phenotype without classic cardiometabolic risk factors, is associated with adverse liver profiles and higher liver-related mortality, highlighting an underrecognized high-risk subgroup within lean SLD populations.

Gastroenterology Internal Medicine news

Cryptogenic Steatotic Liver Disease: A Lean Phenotype Linked to Increased Liver-Related Mortality

By MedXY 08/15/2026

Cryptogenic steatotic liver disease (SLD) is a form of fatty liver disease found in lean individuals without diabetes or other metabolic risk factors, associated with significant liver injury and increased mortality risk.

Clinical Updates Gastroenterology Internal Medicine news

AZD2693: Targeting PNPLA3 148M Variant as a Precision Therapy for Metabolic Steatohepatitis

By MedXY 09/20/2025

AZD2693, a liver-directed antisense oligonucleotide, safely reduces PNPLA3 expression and liver fat in homozygous PNPLA3 148M carriers with metabolic dysfunction-associated steatohepatitis, signaling promise for precision treatment in this genetically defined subgroup.